Treatment of Helicobacter pylori

被引:20
作者
Hoffman, JS [1 ]
Cave, DR [1 ]
机构
[1] St Elizabeths Med Ctr, Div Gastroenterol, Brighton, MA 02135 USA
关键词
D O I
10.1097/00001574-200101000-00006
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Helicobacter pylori causes several gastroduodenal diseases. Various antibiotic regimens are available that eradicate H. pylori in 80 to 90% of patients, but no regimen cures all patients. Dual therapy is now obsolete. Triple therapy with two antibiotics and either a proton pump inhibitor or bismuth is the regimens of choice. Metronidazole and clarithromycin are the two key antibiotics. Antibiotic resistance against these two drugs is becoming more problematic and should be taken into consideration when choosing a regimen, Antibiotic resistance is usually induced after failure. Quadruple therapy has been used as a salvage regimen in failed cases but it is also the most complicated regimen. Several new agents are being studied including a single capsule that contains bismuth, metronidazole, and tetracycline. (C) 2001 Lippincott Williams & Wilkins, Inc.
引用
收藏
页码:30 / 34
页数:5
相关论文
共 34 条
[11]   Insulin-dependent diabetes mellitus affects eradication rate of Helicobacter pylori infection [J].
Gasbarrini, A ;
Ojetti, V ;
Pitocco, D ;
Franceschi, F ;
Candelli, M ;
Torre, ES ;
Gabrielli, M ;
Cammarota, G ;
Armuzzi, A ;
Pola, R ;
Pola, P ;
Ghirlanda, G ;
Gasbarrini, G .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1999, 11 (07) :713-716
[12]  
Gasbarrini A, 2000, SCAND J GASTROENTERO, V35, P260, DOI 10.1080/003655200750024119
[13]  
Gisbert JP, 1999, ALIMENT PHARM THERAP, V13, P1311
[14]  
Graham DY, 2000, ALIMENT PHARM THER, V14, P745
[15]  
Graham DY, 2000, ALIMENT PHARM THERAP, V14, P211
[16]  
Grimley CE, 1999, ALIMENT PHARM THERAP, V13, P869
[17]  
Houben MHMG, 1999, ALIMENT PHARM THER, V13, P1047
[18]   Therapeutic oral vaccination induces mucosal immune response sufficient to eliminate long-term Helicobacter pylori infection [J].
Ikewaki, J ;
Nishizono, A ;
Goto, T ;
Fujioka, T ;
Mifune, K .
MICROBIOLOGY AND IMMUNOLOGY, 2000, 44 (01) :29-39
[19]   Costs and benefits of a test-and-treat strategy in Helicobacter pylori-infected subjects:: a prospective intervention study in general practice [J].
Joosen, EAM ;
Reininga, JHA ;
Manders, JMW ;
ten Ham, JC ;
de Boer, WA .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2000, 12 (03) :319-325
[20]   Immune response to an 18-kilodalton outer membrane antigen identifies lipoprotein 20 as a Helicobacter pylori vaccine candidate [J].
Keenan, J ;
Oliaro, J ;
Domigan, N ;
Potter, H ;
Aitken, G ;
Allardyce, R ;
Roake, J .
INFECTION AND IMMUNITY, 2000, 68 (06) :3337-3343